Matinas Biopharma Holdings Inc [AMEX: MTNB] stock went on an upward path that rose over 4.39% on Monday, amounting to a one-week price increase of more than 6.50%. The company report on March 25, 2024 at 8:00 AM that Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation.
Matinas’ Positivein vivo Safety Data with its Oral LNC-Docetaxel Formulation.
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel.
Over the last 12 months, MTNB stock dropped by -28.96%. The one-year Matinas Biopharma Holdings Inc stock forecast points to a potential upside of 71.0. The average equity rating for MTNB stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $63.05 million, with 217.26 million shares outstanding and 210.93 million shares in the current float. Compared to the average trading volume of 1.34M shares, MTNB stock reached a trading volume of 3043044 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Matinas Biopharma Holdings Inc [MTNB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MTNB shares is $1.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MTNB stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Matinas Biopharma Holdings Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 11, 2021. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on August 26, 2020, representing the official price target for Matinas Biopharma Holdings Inc stock. Previously, the target price had yet another raise to $3, while Piper Sandler analysts kept a Overweight rating on MTNB stock.
The Average True Range (ATR) for Matinas Biopharma Holdings Inc is set at 0.04, with the Price to Sales ratio for MTNB stock in the period of the last 12 months amounting to 29.19. The Price to Book ratio for the last quarter was 2.72, with the Price to Cash per share for the same quarter was set at 0.08.
MTNB Stock Performance Analysis:
Matinas Biopharma Holdings Inc [MTNB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.50. With this latest performance, MTNB shares gained by 21.22% in over the last four-week period, additionally plugging by 116.57% over the last 6 months – not to mention a drop of -28.96% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MTNB stock in for the last two-week period is set at 58.34, with the RSI for the last a single of trading hit 58.74, and the three-weeks RSI is set at 57.79 for Matinas Biopharma Holdings Inc [MTNB]. The present Moving Average for the last 50 days of trading for this stock 0.2371, while it was recorded at 0.2812 for the last single week of trading, and 0.2462 for the last 200 days.
Insight into Matinas Biopharma Holdings Inc Fundamentals:
Matinas Biopharma Holdings Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.19 and a Current Ratio set at 6.19.
MTNB Stock EPS
With the latest financial reports released by the company, Matinas Biopharma Holdings Inc posted -0.02/share EPS, while the average EPS was predicted by analysts to be reported at -0.03/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 33.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MTNB.
Matinas Biopharma Holdings Inc [MTNB] Institutonal Ownership Details
The top three institutional holders of MTNB stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in MTNB stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in MTNB stock with ownership which is approximately 5.8325%.
